Hyperlipidemias: Clinical Trials

13 trials for Hyperlipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Terminated 13
Phase 23Terminated 3

Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
LY3875383, Placebo - Hypertriglyceridemia
Phase 1TerminatedEli Lilly and Company412022-11-142025-06-04
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
STT-5058, Placebo - Hypertriglyceridemia
Phase 1TerminatedStaten Biotechnology BV932020-05-262023-01-23
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
AAV directed hLDLR gene therapy - Homozygous Familial Hypercholesterolemia (HoFH)
Phase 1 / Phase 2TerminatedREGENXBIO Inc.92016-03-012023-07-13
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase
Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20 - Healthy, Hypercholesterolemia
Phase 1TerminatedPfizer602016-02-012016-10-21
Single Dose Study of PF-06815345 in Healthy Subjects
PF-06815345, Placebo - Hypercholesterolemia
Phase 1TerminatedPfizer252015-11-012018-09-28
PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin
YH22189, Twynsta 80/10mg, Crestor 20mg - Hypertension, Hyperlipidemia
Phase 1TerminatedYuhan Corporation1232015-11-012017-02-01
A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia
BMS-852927, Placebo - Hypercholesterolemia
Phase 1TerminatedBristol-Myers Squibb972012-11-012013-08-05
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
MK-0524A - Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia
Phase 1TerminatedMerck Sharp & Dohme LLC102012-06-012015-11-03
Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH
SPC5001, Saline 0.9% - Hypercholesterolemia
Phase 1TerminatedSantaris Pharma A/S242011-05-012011-11-22
Safety Study of BMS-844421 for Treatment of Hypercholesterolemia
BMS-844421, 0.9% sodium chloride injection solution - Atherosclerosis, Hypercholesterolemia
Phase 1TerminatedBristol-Myers Squibb402010-04-012011-01-26
IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Atorvastatin - HIV Infections, Hyperlipidemia
Phase 1 / Phase 2TerminatedInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group282009-08-012016-04-06
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol
PRO-040201, Placebo - Hypercholesterolemia
Phase 1TerminatedArbutus Biopharma Corporation232009-06-012010-01-22
Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients
3,5-Diiodothyropropionic acid (DITPA) therapy - Hypercholesterolemia
Phase 1 / Phase 2TerminatedJohns Hopkins University602006-04-012013-04-02

Narrower conditions

Hypercholesterolemia (7)  ·  Atherosclerosis (2)  ·  Hyperlipoproteinemia Type II (2)  ·  Hypertriglyceridemia (2)  ·  Cardiovascular Diseases (1)  ·  Coronary Artery Disease (1)  ·  Dyslipidemias (1)  ·  Genetic Diseases, Inborn (1)  ·  HIV Infections (1)  ·  Homozygous Familial Hypercholesterolemia (1)  ·  Hypertension (1)  ·  Metabolic Diseases (1)  ·  Rare Diseases (1)

Broader conditions

Lipid Metabolism Disorders (13)  ·  Nutritional and Metabolic Diseases (13)  ·  Dyslipidemias (12)  ·  Metabolic Diseases (12)  ·  Vascular Diseases (4)  ·  Arterial Occlusive Diseases (3)  ·  Arteriosclerosis (3)  ·  Cardiovascular Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Hyperlipoproteinemias (2)  ·  Lipid Metabolism, Inborn Errors (2)  ·  Metabolism, Inborn Errors (2)  ·  Blood-Borne Infections (1)  ·  Communicable Diseases (1)

Interventions

3,5-diiodothyropropionic acid (1)  ·  Amlodipine (1)  ·  Atorvastatin (1)  ·  MK-0524 (1)  ·  Niacin (1)  ·  Rosuvastatin Calcium (1)  ·  SPC5001 (1)  ·  Sodium Chloride (1)  ·  Telmisartan (1)  ·  Therapeutics (1)  ·  telmisartan amlodipine combination (1)

Sponsors

Bristol-Myers Squibb (2)  ·  Pfizer (2)  ·  Arbutus Biopharma Corporation (1)  ·  Eli Lilly and Company (1)  ·  International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1)  ·  Johns Hopkins University (1)  ·  Merck Sharp & Dohme LLC (1)  ·  REGENXBIO Inc. (1)  ·  Santaris Pharma A/S (1)  ·  Staten Biotechnology BV (1)  ·  Yuhan Corporation (1)

Countries

United States (4)  ·  Belgium (2)  ·  Canada (2)  ·  Germany (2)  ·  Netherlands (2)  ·  Italy (1)  ·  Singapore (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Ann Melvin, MD (1)  ·  Annabelle Rodriguez, MD (1)  ·  Douglas Logan, MD (1)  ·  Koos Burggraaf, MD PhD (1)  ·  Marilyn Crain, MD, MPH (1)

Results publications

PMID 26261033, PMID 30623096

NIH funding

2015 (2), 2009 (1), P01HL059407 (1), U01AI068632 (1)